OptimizeRx Corporation (OPRX) Stock Forecast
OPRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $12.60 average of analyst targets
- Upside to target
- +48.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.07
- 52-week range
- $4.54 – $21.68
OPRX analyst ratings
6 analystsNumber of analysts at each rating.
OPRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OPRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.16 | $0.10 | $0.22 | $0.20 | −19.0% | 5 |
| Current fiscal year (2026) | $0.88 | $0.72 | $0.99 | $1.05 | −16.6% | 5 |
| Next fiscal year (2027) | $1.04 | $0.78 | $1.35 | $0.88 | +19.2% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OPRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $21.2M | $20.5M | $21.5M | −18.7% | 6 |
| Current fiscal year (2026) | $96.2M | $95.0M | $98.0M | −12.1% | 6 |
| Next fiscal year (2027) | $106.6M | $102.6M | $118.9M | +10.8% | 6 |
OPRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OPRX revenue: reported and forecast
OPRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.25 | $0.25 | $0.17 | $0.17 | $0.16 | −34.1% | 0 up · 1 down |
| Current fiscal year (2026) | $0.94 | $0.94 | $0.89 | $0.89 | $0.88 | −6.6% | 0 up · 1 down |
| Next fiscal year (2027) | $1.09 | $1.09 | $1.06 | $1.06 | $1.04 | −4.4% | 3 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OPRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OPRX beat in 9 of 12.
What analysts expect from OPRX
6 analysts cover OptimizeRx; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.60, 48.2% above the latest close of $8.50. Analysts expect earnings of $0.88 per share for 2026, −16.6% from a year earlier. For 2027 the average estimate is $1.04 per share on revenue of $106.6 million. OptimizeRx beat the EPS estimate in 9 of the last 12 quarters.
Related: OPRX income statement, OPRX key metrics, OPRX chart. See the OPRX stock overview for the latest quote and news.
OPRX forecast FAQ
What is OptimizeRx's price target?
The average analyst price target for OptimizeRx is $12.60, 48.2% above the latest close of $8.50.
Is OptimizeRx a buy, hold or sell?
Of 6 analysts covering OptimizeRx, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is OptimizeRx's EPS forecast?
Analysts forecast $0.88 per share for 2026 (range $0.72 to $0.99); for 2027 the estimate is $1.04.
What is OptimizeRx's revenue forecast?
The average revenue estimate for 2026 is $96.2 million, growth of −12.1%; for 2027 it is $106.6 million.
When does OptimizeRx report earnings?
OptimizeRx is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $0.07.
Does OptimizeRx usually beat earnings estimates?
OptimizeRx reported EPS at or above the analyst estimate in 9 of the last 12 quarters.